GLP-1 side effects vs Tirzepatide: Dosage, Price, Results Compared

GLP-1 medications have become the gold standard in medical weight loss. Among them, semaglutide (used in Ozempic and Wegovy) and tirzepatide (the active ingredient in Mounjaro and Zepbound) are leading the way. While both are highly effective, patients often ask how they compare when it comes to side effects, dosing, results, and affordability.

Here’s what you need to know if you’re deciding between these two powerful weight loss treatments.

Mechanism: How They Work

Both semaglutide and tirzepatide target gut hormones that regulate appetite and insulin response—but with one key difference:

• Semaglutide acts on the GLP-1 receptor only.
• Tirzepatide targets GLP-1 and GIP receptors, giving it a dual action for appetite control and metabolic regulation.

This dual mechanism is what makes tirzepatide potentially more effective, but also slightly more intense in terms of side effects.

Side Effects Compared

GLP-1 (Semaglutide) Common Side Effects:

• Nausea (especially early on)
• Constipation
• Diarrhea or mild bloating
• Fatigue
• Reduced appetite

Tirzepatide (Mounjaro) Common Side Effects:

• Nausea (may be stronger at higher doses)
• Burping or gas
• Diarrhea or constipation
• Mild headache
• Appetite suppression that may feel more intense

Key Difference: Tirzepatide’s stronger effect on both hormone pathways means patients may feel more digestive disruption in the beginning, especially when increasing the dose.

With both medications, side effects typically fade after a few weeks if dosing is increased gradually and paired with dietary adjustments.

Dosage Comparison

Semaglutide (GLP-1):

• Starts at 0.25 mg weekly
• Increased to 0.5 mg, 1.0 mg, and possibly up to 2.4 mg
• Weekly injection, easy to self-administer

Tirzepatide:

• Starts at 2.5 mg weekly
• Can increase to 5 mg, 10 mg, and up to 15 mg
• Also once-weekly injection, slightly thicker formulation

Both medications require step-up protocols to help minimize side effects. Your provider will customize your dosage plan based on how your body responds.

Weight Loss Results Compared

• Semaglutide: Up to 15% total body weight loss reported in clinical trials
• Tirzepatide: Patients report up to 20–22% weight loss, especially at higher doses

Both are impressive, but tirzepatide may provide faster and deeper fat loss—making it ideal for patients with higher starting weight or insulin resistance.

Cost Comparison in 2025

At retail pharmacies, both medications remain expensive without insurance:

• Semaglutide (Ozempic/Wegovy): $1,300–$1,500/month
• Tirzepatide (Mounjaro/Zepbound): $1,200–$1,400/month

Affordable Option: Telehealth platforms like Meya now offer compounded versions of both drugs at a flat $196/month—no insurance needed.

This includes:

• Online provider consultation
• Prescription if eligible
• Medication shipped to your door
• Ongoing support and dose adjustment

Which One Should You Choose?

Choose Semaglutide if:

• You prefer a more established option
• You want a milder start with fewer digestive symptoms
• You’re looking for steady, long-term progress

Choose Tirzepatide if:

• You want more aggressive weight loss
• You can tolerate stronger side effects in exchange for faster results
• You’ve already tried semaglutide and hit a plateau

Conclusion: Two Powerful Options, One Affordable Path

Both GLP-1 and tirzepatide offer life-changing results. The difference comes down to your goals, tolerance, and how quickly you want to see results. With affordable telehealth pricing, you no longer have to choose based on cost.

Want real GLP-1 or tirzepatide treatment without the $1,300/month price tag? Start your journey with Meya for just $196/month.